This study is looking at whether sparsentan can help reduce high levels of protein in the urine (proteinuria) for people with cancer who are also taking certain other cancer medications called VEGF signaling pathway inhibitors (VSPIs). You might be able to join if you are an adult (18 or older) with cancer, are currently taking VSPIs, and have new, high-grade proteinuria. The study will measure the change in your urine protein levels after 8 weeks to see if sparsentan is effective. The current recruitment status is unclear.

Study design

This is a single-center, open-label pilot study. It plans to include 20 participants.

What's involved

Participants will take sparsentan 200 mg daily for 2 weeks, then increase to 400 mg daily. Your urine protein to creatinine ratio will be assessed from screening to week 8.

Compensation

Not stated in the trial record.

Follow-up

Your urine protein levels will be measured at 8 weeks after starting the study.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.